Genezen Secures $18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities

Financing led by Ampersand Capital Partners with significant support from Genezen’s management team and advisors Proceeds from financing will enable expansion of Genezen’s viral vector development and manufacturing capacity and capabilities Pipeline of multiple client programs are fueling…